Literature DB >> 8985286

Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss.

M D Stegall1, G T Everson, G Schroter, F Karrer, B Bilir, T Sternberg, R Shrestha, M Wachs, I Kam.   

Abstract

We prospectively withdrew prednisone in 28 adult patients who had stable graft function more than 2 years after orthotopic liver transplantation (OLTx) and had been on 5 mg/d prednisone for at least 6 months. Prednisone was decreased from 5 mg/d to 2.5 mg/d for 1 month then stopped completely. Cyclosporine monotherapy was maintained at a level of approximately 200 ng/mL (TDX). Nineteen patients had prednisone withdrawn without complications. Four (14.2%) had modest elevations in liver function tests (two biopsy proven mild rejections and two were not biopsied). These four were treated with methylprednisolone boluses and then withdrawal of steroids again. Prednisone was restarted in five patients because of generalized fatigue and body aches (n = 4) and colitis (n = 1). Steroids later were successfully withdrawn in two of these patients. After prednisone withdrawal, three of five insulin-dependent diabetic patients were able to discontinue insulin therapy and their glycosylated hemoglobin levels improved. Four of fourteen hypertensive patients were able to discontinue antihypertensive medicines. Mean serum cholesterol decreased from 222.6 +/- 43.3 to 188.3 +/- 33.3 mg/dL (P < .001). The number of patients with serum cholesterol levels > 220 mg/dL decreased from 13 to 4. A control group of 24 patients maintained on 5 mg/d prednisone at least 2 years after liver transplantation also was studied. In this group during the study period, no diabetic became normoglycemic, no patient decreased their antihypertensive medicine, and the mean serum cholesterol levels did not change significantly. We conclude that prednisone withdrawal using cyclosporine monotherapy late after liver transplantation does not lead to graft loss and decreases the prevalence of diabetes, hypertension, and hypercholesterolemia. Symptoms occurring during withdrawal may be minimized by earlier or slower tapering.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8985286     DOI: 10.1002/hep.510250132

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  16 in total

1.  Transplantation of primary and reversibly immortalized human liver cells and other gene therapies in acute liver failure and decompensated chronic liver disease.

Authors:  Stephen M Riordan; Roger Williams
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

Review 2.  Orthotopic liver transplantation and what to do during follow-up: recommendations for the practitioner.

Authors:  Daniel Benten; Katharina Staufer; Martina Sterneck
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-11-25

Review 3.  Efficacy of immunosuppression monotherapy after liver transplantation: a meta-analysis.

Authors:  Xiang Lan; Meng-Gang Liu; Hong-Xu Chen; Hong-Ming Liu; Wei Zeng; Dong Wei; Ping Chen
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 4.  The metabolic effects of cyclosporin and tacrolimus.

Authors:  P Marchetti; R Navalesi
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

Review 5.  Long-term medical management of the liver transplant recipient: what the primary care physician needs to know.

Authors:  Siddharth Singh; Kymberly D Watt
Journal:  Mayo Clin Proc       Date:  2012-07-03       Impact factor: 7.616

6.  Early steroid withdrawal after liver transplantation for hepatocellular carcinoma.

Authors:  Zhi-Shui Chen; Fan He; Fan-Jun Zeng; Ji-Pin Jiang; Dun-Feng Du; Bin Liu
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

Review 7.  Single-agent immunosuppression after liver transplantation: what is possible?

Authors:  Maria L Raimondo; Andrew K Burroughs
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  Metabolic complications in liver transplant recipients.

Authors:  Miguel Jiménez-Pérez; Rocío González-Grande; Edith Omonte Guzmán; Víctor Amo Trillo; Juan Miguel Rodrigo López
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

9.  Liver transplantation().

Authors:  M Rossi; G Mennini; Q Lai; S Ginanni Corradini; F M Drudi; F Pugliese; P B Berloco
Journal:  J Ultrasound       Date:  2007-04-16

10.  Metabolic syndrome after liver transplantation: preventable illness or common consequence?

Authors:  Eric R Kallwitz
Journal:  World J Gastroenterol       Date:  2012-07-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.